摘要:
Objective To detect the clinical effect of Yixuesheng Capsule on white blood cell decline in gynecological tumor patients undergoing chemotherapy and its clinical efficacy.Methods Atotal of 124 gynecological tumor patients with white blood cell decline were enrolled in this study.Patients were randomly divided into control group (n =62) and observation group (n =62).The control group were given rhG-CSF treatment,and the observation group were treated with Yixuesheng Capsule and rhG-CSE The blood cell count,Spitzer score,Cares-SF score,and adverse reaction were compared.Results There was no significant difference of white blood cell (WBC),red blood cell (RBC),and platelet counts.After treatment,the WBC,RBC,and platelet count were significantly increased in the two groups (P < 0.05,0.01).But the observation group was better than the control group (P < 0.05) on the increase of WBC,RBC,and platelet.There was no significant difference of Spitzer score and Cares-SF score between the two groups before treatment.After treatment,Spitzer scores of the two groups were significantly increased and Cares-SF scores were significantly decreased (P < 0.05,0.01),but the observation group of Spitzer score increased and Cares-SF score decreased superior than those of the control group (P < 0.05).The incidence of infection in observation group was 22.6% (14/62),which was significantly lower than that of 38.7% (24/62) in control group (P < 0.05).The usage ofrhG-CSF in control group was 17.24 ± 3.52,which was significantly higher than that of 12.14 ± 2.73 in observation group (P < 0.05).The rate of adverse reaction was 8.1% (5/62) in observation group which was lower than that of 21.0% (l 3/62) in control group (P < 0.05).Conclusion Yixuesheng Capsule can significantly increase the blood cells of gynecological tumor patients undergoing chemotherapy,improve the clinical symptoms and the quality of life,with significantly clinical safety.%目的 观察益血生胶囊联合人粒细胞集落刺激因子对妇科肿瘤化疗后白细胞下降的临床疗效,并探讨了其临床使用安全性.方法 收集2013年4月-2015年8月周口市中医院治疗的妇科肿瘤化疗后白细胞下降患者124例,使用数字法随机分为对照组和观察组,每组62例.对照组给予人粒细胞集落刺激因子,150 μg/d,皮下注射,1次/d,观察组在对照组基础上加用益血生胶囊,4粒/次,口服,3次/d,4周为1疗程.比较两组治疗前后血细胞计数、Spitzer生存质量指数评分量表(Spitzer评分)和癌症康复评价简表(Cares-SF评分)以及治疗期间不良反应发生率的差异.结果 两组治疗前白细胞、红细胞和血小板计数均无显著性差异,治疗后两组白细胞、红细胞和血小板计数均出现显著升高(P<0.05、0.01),但观察组对白细胞、红细胞和血小板的升高作用优于对照组(P<0.05).两组治疗前Spitzer和Cares-SF评分均无显著性差异,治疗后两组Spitzer评分均出现显著升高和Cares-SF评分均出现显著减低(P<0.05、0.01),但观察组对Spitzer评分的升高作用以及Cares-SF评分的减低作用优于对照组(P<0.05).观察组感染发生率为22.6%(14/62)显著低于对照组的38.7%(24/62)(P<0.05).对照组人粒细胞集落刺激因子使用(17.24±3.52)支,显著高于观察组的(12.14±2.73)支(P<0.05).观察组临床治疗不良反应率为8.1% (5/62),显著低于对照组的21.0% (13/62) (P<0.05).结论 益血生胶囊联合人粒细胞集落刺激因子可显著升高妇科肿瘤化疗后白细胞下降患者的血细胞,改善患者临床症状,提高生活质量,临床使用安全.